Outlook Therapeutics Inc (NASDAQ: OTLK)’s stock price has plunge by 15.65relation to previous closing price of 1.47. Nevertheless, the company has seen a 21.43% surge in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-13 that ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that following an internal strategic review, the management team and Board of Directors have implemented initiatives to streamline the organization, reduce operating expenses and preserve capital, with the goal of maximizing its efforts to commercially launch LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) and supporting the resubmission of the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ to the U.S. Food and Drug Administration (FDA).
Is It Worth Investing in Outlook Therapeutics Inc (NASDAQ: OTLK) Right Now?
The 36-month beta value for OTLK is also noteworthy at 0.54. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for OTLK is 15.23M, and at present, short sellers hold a 23.03% of that float. The average trading volume of OTLK on December 27, 2024 was 1.65M shares.
OTLK’s Market Performance
The stock of Outlook Therapeutics Inc (OTLK) has seen a 21.43% increase in the past week, with a -65.52% drop in the past month, and a -70.07% fall in the past quarter. The volatility ratio for the week is 13.69%, and the volatility levels for the past 30 days are at 20.10% for OTLK. The simple moving average for the past 20 days is 6.83% for OTLK’s stock, with a -74.40% simple moving average for the past 200 days.
Analysts’ Opinion of OTLK
BTIG Research, on the other hand, stated in their research note that they expect to see OTLK reach a price target of $50. The rating they have provided for OTLK stocks is “Buy” according to the report published on March 27th, 2024.
Chardan Capital Markets gave a rating of “Buy” to OTLK, setting the target price at $3 in the report published on February 15th of the current year.
OTLK Trading at -57.71% from the 50-Day Moving Average
After a stumble in the market that brought OTLK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.77% of loss for the given period.
Volatility was left at 20.10%, however, over the last 30 days, the volatility rate increased by 13.69%, as shares sank -65.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -66.80% lower at present.
During the last 5 trading sessions, OTLK rose by +21.43%, which changed the moving average for the period of 200-days by -75.69% in comparison to the 20-day moving average, which settled at $1.5912. In addition, Outlook Therapeutics Inc saw -78.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OTLK starting from KENYON LAWRENCE A, who purchase 5,000 shares at the price of $5.69 back on Sep 26 ’24. After this action, KENYON LAWRENCE A now owns 5,946 shares of Outlook Therapeutics Inc, valued at $28,446 using the latest closing price.
Haddadin Yezan Munther, the Director of Outlook Therapeutics Inc, purchase 1,882 shares at $11.82 during a trade that took place back on Mar 28 ’24, which means that Haddadin Yezan Munther is holding 5,049 shares at $22,242 based on the most recent closing price.
Stock Fundamentals for OTLK
The total capital return value is set at -13.51.
Based on Outlook Therapeutics Inc (OTLK), the company’s capital structure generated -0.63 points at debt to capital in total, while cash flow to debt ratio is standing at -1.99. The debt to equity ratio resting at -0.39. The interest coverage ratio of the stock is -0.0.
Currently, EBITDA for the company is -57.38 million with net debt to EBITDA at 0.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.07.
Conclusion
In summary, Outlook Therapeutics Inc (OTLK) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
